Latest news with #AfricanMedicinesAgency
Maroc
6 days ago
- Health
- Maroc
Morocco Reiterates in Kigali Commitment to African Health Sovereignty
Morocco reaffirmed on Wednesday in Kigali its commitment to African health sovereignty and to the progressive and inclusive implementation of the African Medicines Agency (AMA). Speaking at the 2nd ordinary session of the Conference of the States Parties to the AMA Treaty, held on June 2-4, Minister of Health and Social Protection Amine Tahraoui hailed the creation of the Agency as a major step towards the continent's health sovereignty, enabling better access to safe, effective and quality medicines. To Morocco, this continental momentum is a source of inspiration and an opportunity for regulatory convergence,' the Minister emphasized, stressing the importance of an approach tailored to the institutional and regulatory realities of each country, based on listening, consultation and respect for national priorities. Tahraoui then called for the progressive harmonization of regulatory frameworks, the establishment of regular consultation mechanisms between national authorities and AMA, and the reinforcement of technical and human capacities on a continental scale. Tahraoui also pointed out that by end 2024, the Kingdom had achieved 88% coverage in compulsory health insurance, adding that 11 million people benefited from direct state support. A $4.2 billion health infrastructure modernization program is underway, he stated, adding that the number of university hospital centers will go from 6 to 12, while 79 new hospitals are under construction, and 1,439 primary health centers are being renovated, 70% of them in rural areas. On the industrial front, Tahraoui noted that Morocco is the continent's second-largest pharmaceutical producer, with 56 industrial units covering 70% of national needs and exports to over 45 African countries. With regard to the appointment of AMA's future Director General, Tahraoui spoke of Morocco's respect to the institutional process currently underway and full confidence in the competent commission to carry it out, in all transparency and impartiality. (MAP: 04 June 2025)
Yahoo
08-05-2025
- Business
- Yahoo
DIA 2025 Global Annual Meeting Spotlights the Power of Collaboration Amid Shifting Regulatory Priorities
Meeting will deliver real-time insight, cross-border coordination, and actionable solutions in the face of uncertainty and change WASHINGTON, May 08, 2025--(BUSINESS WIRE)--DIA, a global non-profit organization of life sciences professionals, will unite thousands of stakeholders to address the future of international regulatory cooperation during the DIA 2025 Global Annual Meeting from June 15-19 in Washington. As policy shifts and regulatory relationships grow more uncertain, DIA 2025 gives the global life sciences community a place to confront these changes as they're unfolding. Recent changes in international health policy have underscored the need for collective action and raised fresh concerns about the fragmentation of global health efforts. At the same time, encouraging steps toward regulatory convergence continue emerging, including the establishment of the African Medicines Agency and Japan aligning its post-marketing surveillance practices with U.S. and European standards. The need for coordinated action has never been greater. DIA 2025 offers the scientific community an opportunity to share information, align on healthcare goals, and tackle the industry's most pressing challenges head-on. With more than 200 sessions across 12 content tracks, the event welcomes regulators, researchers, advocates, and innovators from nearly 50 countries to confront how shifting priorities and policy changes are reshaping innovation, access, and global collaboration. "Scientific progress relies on transparency, access, and evidence," said Marwan Fathallah, DIA's President and Global Chief Executive. "At a time of change, we must not lose sight of our mission of advancing science to improve patient lives. DIA 2025 will be where the global community comes together to solve problems, share knowledge, strengthen collaboration, and drive better outcomes for people everywhere." As a global life sciences association committed to supporting professionals throughout their careers, DIA is offering one year of DIA membership and complimentary registration to the U.S. Food and Drug Administration, National Institutes of Health, and Department of Health and Human Services professionals who were recently laid off. Impacted individuals should complete this form to process their request. The new "Career Connections" initiative will provide networking opportunities and foster connections with employers during their career transitions. An FDA Appreciation Event, open to all registrants, will honor the contributions of professionals past and present who make the industry possible. Keynote speakers Jimi Olaghere, a sickle cell disease advocate whose experience receiving CRISPR-based gene therapy represents a powerful milestone in patient-led innovation, and Dr. Doug Melton, a distinguished research fellow at Vertex Pharmaceuticals who is renowned for his stem cell research, will address the impact of scientific progress and aligning regulatory systems with innovation. Regulatory town halls will again be cornerstones of the conference program. Representatives from several global health authorities, including U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), will share updates on their initiatives and discuss harmonization strategies. As always, DIAmond sessions will tackle the life sciences' most pressing challenges. One will focus on how Identification of Medicinal Products (IDMP) standards can address global healthcare challenges. Another will explore rare disease treatment development, including market access and pricing after accelerated approval. A third will center on the importance of including women in clinical trials and redesigning research policies to reflect that priority. Ethics and patient-centered approaches will be woven throughout the program. Additional topics include real-world data (RWD) collection, using AI in pharmacovigilance and safety monitoring, the latest on ICH E6(R3) implementation, recent changes to the Declaration of Helsinki, and regulatory strategies tailored to emerging markets. Government attendees can now register for DIA 2025 at the reduced rate of $665. Late rates for industry professionals take effect after May 15, so early registration is encouraged. Click here for the event program. Media members can request credentials by emailing diaglobal@ About DIA DIA is a leading global non-profit life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries. Learn more at and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram. View source version on Contacts Media Contacts Katie KennedyGregory FCAdiaglobal@ 610-731-1045 Kali GillGregory FCAdiaglobal@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
08-05-2025
- Business
- Business Wire
DIA 2025 Global Annual Meeting Spotlights the Power of Collaboration Amid Shifting Regulatory Priorities
WASHINGTON--(BUSINESS WIRE)-- DIA, a global non-profit organization of life sciences professionals, will unite thousands of stakeholders to address the future of international regulatory cooperation during the DIA 2025 Global Annual Meeting from June 15-19 in Washington. As policy shifts and regulatory relationships grow more uncertain, DIA 2025 gives the global life sciences community a place to confront these changes as they're unfolding. Recent changes in international health policy have underscored the need for collective action and raised fresh concerns about the fragmentation of global health efforts. At the same time, encouraging steps toward regulatory convergence continue emerging, including the establishment of the African Medicines Agency and Japan aligning its post-marketing surveillance practices with U.S. and European standards. The need for coordinated action has never been greater. DIA 2025 offers the scientific community an opportunity to share information, align on healthcare goals, and tackle the industry's most pressing challenges head-on. With more than 200 sessions across 12 content tracks, the event welcomes regulators, researchers, advocates, and innovators from nearly 50 countries to confront how shifting priorities and policy changes are reshaping innovation, access, and global collaboration. "Scientific progress relies on transparency, access, and evidence," said Marwan Fathallah, DIA's President and Global Chief Executive. "At a time of change, we must not lose sight of our mission of advancing science to improve patient lives. DIA 2025 will be where the global community comes together to solve problems, share knowledge, strengthen collaboration, and drive better outcomes for people everywhere." As a global life sciences association committed to supporting professionals throughout their careers, DIA is offering one year of DIA membership and complimentary registration to the U.S. Food and Drug Administration, National Institutes of Health, and Department of Health and Human Services professionals who were recently laid off. Impacted individuals should complete this form to process their request. The new "Career Connections" initiative will provide networking opportunities and foster connections with employers during their career transitions. An FDA Appreciation Event, open to all registrants, will honor the contributions of professionals past and present who make the industry possible. Keynote speakers Jimi Olaghere, a sickle cell disease advocate whose experience receiving CRISPR-based gene therapy represents a powerful milestone in patient-led innovation, and Dr. Doug Melton, a distinguished research fellow at Vertex Pharmaceuticals who is renowned for his stem cell research, will address the impact of scientific progress and aligning regulatory systems with innovation. Regulatory town halls will again be cornerstones of the conference program. Representatives from several global health authorities, including U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), will share updates on their initiatives and discuss harmonization strategies. As always, DIAmond sessions will tackle the life sciences' most pressing challenges. One will focus on how Identification of Medicinal Products (IDMP) standards can address global healthcare challenges. Another will explore rare disease treatment development, including market access and pricing after accelerated approval. A third will center on the importance of including women in clinical trials and redesigning research policies to reflect that priority. Ethics and patient-centered approaches will be woven throughout the program. Additional topics include real-world data (RWD) collection, using AI in pharmacovigilance and safety monitoring, the latest on ICH E6(R3) implementation, recent changes to the Declaration of Helsinki, and regulatory strategies tailored to emerging markets. Government attendees can now register for DIA 2025 at the reduced rate of $665. Late rates for industry professionals take effect after May 15, so early registration is encouraged. Click here for the event program. Media members can request credentials by emailing diaglobal@ About DIA DIA is a leading global non-profit life science membership association that drives collaboration in drug, device, and diagnostics development in pursuit of a healthier world. Founded in 1964 with headquarters in Washington, D.C., and offices in Europe and Asia, DIA provides unparalleled networking opportunities, educational resources, scientific research publications, and professional development programs to members in more than 80 countries. Learn more at and connect with DIA on LinkedIn, Facebook, X (Twitter), and Instagram.
Zawya
07-02-2025
- Health
- Zawya
Kenya Endorses Communique on Advancing Health Products Manufacturing
African Union (AU) Member States have endorsed a communiqué aimed at strengthening local manufacturing of vaccines, diagnostics, medicines, and other essential health products. Kenya's delegation, led by Principal Secretary for Medical Services Harry Kimtai, joined regional leaders in supporting key commitments to enhance health security and self-sufficiency across the continent. The communiqué highlights the upgrade of the Partnerships for African Vaccine Manufacturing (PAVM) to the Platform for Harmonized African Health Manufacturing (PHAHM) to drive self-reliance, the establishment of the African Pooled Procurement Mechanism (APPM) to improve affordability and access, and the strengthening of regulatory frameworks through the African Medicines Regulatory Harmonization (AMRH) and the African Medicines Agency (AMA). It also supports the Gavi African Vaccine Manufacturing Accelerator (AVMA), a $1.2 billion initiative to boost vaccine production, while promoting regional collaboration and financing mechanisms to sustain investments in Africa's health manufacturing sector. The forum urged AU Member States, regional economic communities, and global partners to prioritize procurement of African-made vaccines and health products to ensure demand certainty for local manufacturers. It also called for stronger commitments to talent development, financing, and coordinated procurement strategies to reduce import dependency. Kenya reaffirmed its commitment to advancing these initiatives, aligning with the AU's vision for a resilient and self-reliant health system across the continent. Distributed by APO Group on behalf of Ministry of Health, Kenya.
